MOA Life Plus Co. Ltd.
KOSDAQ-listed developer of immune-modulating drugs via HumaMAX/MucoMAX platforms, alongside health-supplement and cosmetics businesses.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1999 and listed on KOSDAQ in 2016, MOA Life Plus is an immune-modulating drug developer and healthcare company. Based on its proprietary HumaMAX and MucoMAX platforms, it develops BLS-H01 for cervical intraepithelial neoplasia, BLS-M07 for cervical precancer, BLS-M22 for Duchenne muscular dystrophy, and BLS-M32 for age-related sarcopenia, alongside health-supplement, cosmetics, and pharmaceutical distribution businesses. BLS-H01 completed Phase 2 trials for cervical intraepithelial neoplasia and was also developed as a COVID-19 treatment, receiving Phase 2 IND approval from the MFDS in March 2022 before early termination as the pandemic became endemic; its poly-γ-glutamic acid ingredient received New Dietary Ingredient (NDI) approval from the US FDA and is supplied to Europe under a contract with a Swiss-based global company.
Products & technology
- BLS-H01Treatment for cervical intraepithelial neoplasia (CIN1) / COVID-19 treatment candidate
- BLS-M07Cervical precancer treatment
- BLS-M22Duchenne muscular dystrophy treatment
- BLS-M32Age-related sarcopenia treatment
- ImmuneN PGA-KHealth functional food
- Doctors PGA / Skinnova7Skincare cosmetics and beauty device
R&D and key agreements
Source: DART corporate disclosureBLS-H01 · 자궁경부상피이형증(CIN1) · 임상 2상 완료
BLS-H01(약물재창출) · COVID-19(SARS-CoV-2) · 임상 2상 IND 승인 후 조기종료 · Phase 2 IND approved by MFDS in March 2022, terminated early due to endemic transition
백신보조제/면역관문억제제 병용 항암제 후보 · 항암 백신 보조제/병용요법 · 기초연구·비임상 · Based on poly-γ-glutamic acid
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIChatGPT-Useranswer5
- OpenAIOAI-SearchBot3
Measured since Aug 25, 2026 · 1 AI engines · last read Aug 27, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition